Literature DB >> 16912167

Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1+/- mice.

Catherine Wilson1, Cleo Bonnet, Carol Guy, Shelley Idziaszczyk, James Colley, Vikki Humphreys, Julie Maynard, Julian R Sampson, Jeremy P Cheadle.   

Abstract

Tuberous sclerosis complex (TSC) is caused by mutations in either the TSC1 or TSC2 gene. Both genes are generally considered to act as tumor suppressors that fulfill Knudson's "two-hit hypothesis" and that function within the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin (mTOR) pathway. We previously generated Tsc1(+/-) mice that are predisposed to renal cysts, which develop into cystadenomas and renal cell carcinomas. Here, we identified somatic Tsc1 mutations (second hits) in approximately 80% of cystadenomas and renal cell carcinomas, but only 31.6% of cysts from Tsc1(+/-) mice (P < 0.0003), raising the possibility that haploinsufficiency for Tsc1 plays a role in cyst formation. Consistent with this proposal, many cysts showed little or no staining for phosphorylated mTOR (53%) and phosphorylated S6 ribosomal protein (37%), whereas >90% of cystadenomas and renal cell carcinomas showed strong staining for both markers (P < 0.0005). We also sought somatic mutations in renal lesions from Tsc1(+/-) Blm(-/-) mice that have a high frequency of somatic loss of heterozygosity, thereby facilitating the detection of second hits. We also found significantly less somatic mutations in cysts as compared with cystadenomas and renal cell carcinomas from these mice (P = 0.017). Our data indicate that although activation of the mTOR pathway is an important step in Tsc-associated renal tumorigenesis, it may not be the key initiating event in this process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912167     DOI: 10.1158/0008-5472.CAN-06-1740

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Tuberous sclerosis complex: new insights into clinical and therapeutic approach.

Authors:  Angela Volpi; Gabriele Sala; Elena Lesma; Francesca Labriola; Marco Righetti; Rosa Maria Alfano; Mario Cozzolino
Journal:  J Nephrol       Date:  2018-11-07       Impact factor: 3.902

2.  Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin.

Authors:  Itzamarie Chévere-Torres; Jordan M Maki; Emanuela Santini; Eric Klann
Journal:  Neurobiol Dis       Date:  2011-07-30       Impact factor: 5.996

3.  Cilia and cilia-associated proteins in cancer.

Authors:  Tamina Seeger-Nukpezah; Joy L Little; Victoria Serzhanova; Erica A Golemis
Journal:  Drug Discov Today Dis Mech       Date:  2013-12-01

4.  Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex.

Authors:  B Patel; J Patel; J-H Cho; S Manne; S Bonala; E Henske; F Roegiers; M Markiewski; M Karbowniczek
Journal:  Oncogene       Date:  2015-10-05       Impact factor: 9.867

5.  Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.

Authors:  Lisa M Julian; Sean P Delaney; Ying Wang; Alexander A Goldberg; Carole Doré; Julien Yockell-Lelièvre; Roger Y Tam; Krinio Giannikou; Fiona McMurray; Molly S Shoichet; Mary-Ellen Harper; Elizabeth P Henske; David J Kwiatkowski; Thomas N Darling; Joel Moss; Arnold S Kristof; William L Stanford
Journal:  Cancer Res       Date:  2017-08-22       Impact factor: 12.701

Review 6.  Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).

Authors:  David J Kwiatkowski
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

Review 7.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Authors:  Vera P Krymskaya
Journal:  Proc Am Thorac Soc       Date:  2008-01-01

8.  A role for p38 stress-activated protein kinase in regulation of cell growth via TORC1.

Authors:  Megan Cully; Alice Genevet; Patricia Warne; Caroline Treins; Tao Liu; Julie Bastien; Buzz Baum; Nic Tapon; Sally J Leevers; Julian Downward
Journal:  Mol Cell Biol       Date:  2009-11-16       Impact factor: 4.272

9.  Pml represses tumour progression through inhibition of mTOR.

Authors:  Rosa Bernardi; Antonella Papa; Ainara Egia; Nadia Coltella; Julie Teruya-Feldstein; Sabina Signoretti; Pier Paolo Pandolfi
Journal:  EMBO Mol Med       Date:  2011-03-08       Impact factor: 12.137

10.  Comparative immunohistochemical analysis of ochratoxin A tumourigenesis in rats and urinary tract carcinoma in humans; mechanistic significance of p-S6 ribosomal protein expression.

Authors:  Patrycja Gazinska; Diana Herman; Cheryl Gillett; Sarah Pinder; Peter Mantle
Journal:  Toxins (Basel)       Date:  2012-09-11       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.